-
平臺編號：bio-69186
-
國際編號：HTB-112?
-
細(xì)胞信息： HEC-1-A
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
HEC-1-A
是否是腫瘤細(xì)胞：1
物種來源：人
組織來源：endometrium
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
器官來源：子宮
細(xì)胞形態(tài)：上皮樣
生長狀態(tài)：貼壁生長
年限：71 years
ATCC Number：HTB-112?
相關(guān)疾?。合侔?br /> 規(guī)格：0.1mg Designations: HEC-1-A
Depositors: ?H Kuramoto
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: uterus
Tissue: endometrium
Disease: adenocarcinoma
Cellular Products:platelet activating factor (PAF)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:platelet activating factor (PAF)
Tumorigenic:Yes
Oncogene:c-fos +
Antigen Expression:Blood Type B; Rh+
Cytogenetic Analysis:hypodiploid to hyperdiploid, modal number = 47 with large metacentric marker
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 2
Me-2, 1
PGM1, 1
PGM3, 1-2
Age: 71 years
Gender: female
Comments:This line and a substrain HEC-1-B (ATCC HTB-113 ) were isolated in 1968 by H. Kuramoto and associates from a patient with stage IA endometrial cancer.
PAF induces increased expression of c-fos.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
recommended serum:ATCC 30-2020
References: 22449: Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet. Gynaecol. Jpn. 19: 47-58, 1972. PubMed: 4678779
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
23069: Presta M, et al. Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. Cancer Res. 48: 6384-6389, 1988. PubMed: 3263185
23115: Maggi M, et al. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. Cancer Res. 54: 4777-4784, 1994. PubMed: 7520361
23541: Kuramoto H, et al. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 114: 1012-1019, 1972. PubMed: 4673779
29988: Hendricks DT, et al. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57: 2112-2115, 1997. PubMed: 9187105
物種來源：人
組織來源：endometrium
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
器官來源：子宮
細(xì)胞形態(tài)：上皮樣
生長狀態(tài)：貼壁生長
年限：71 years
ATCC Number：HTB-112?
相關(guān)疾?。合侔?br /> 規(guī)格：0.1mg Designations: HEC-1-A
Depositors: ?H Kuramoto
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: uterus
Tissue: endometrium
Disease: adenocarcinoma
Cellular Products:platelet activating factor (PAF)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:platelet activating factor (PAF)
Tumorigenic:Yes
Oncogene:c-fos +
Antigen Expression:Blood Type B; Rh+
Cytogenetic Analysis:hypodiploid to hyperdiploid, modal number = 47 with large metacentric marker
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 2
Me-2, 1
PGM1, 1
PGM3, 1-2
Age: 71 years
Gender: female
Comments:This line and a substrain HEC-1-B (ATCC HTB-113 ) were isolated in 1968 by H. Kuramoto and associates from a patient with stage IA endometrial cancer.
PAF induces increased expression of c-fos.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
recommended serum:ATCC 30-2020
References: 22449: Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet. Gynaecol. Jpn. 19: 47-58, 1972. PubMed: 4678779
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
23069: Presta M, et al. Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. Cancer Res. 48: 6384-6389, 1988. PubMed: 3263185
23115: Maggi M, et al. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. Cancer Res. 54: 4777-4784, 1994. PubMed: 7520361
23541: Kuramoto H, et al. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 114: 1012-1019, 1972. PubMed: 4673779
29988: Hendricks DT, et al. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57: 2112-2115, 1997. PubMed: 9187105
